AMPLIFY - D6571C00001 Duaklir USA Phase III Study

A 24 Week Treatment, Multicenter, Randomized, Double Blinded, Double Dummy, Parallel-group, Clinical Trial Evaluating the Efficacy and Safety of Aclidinium Bromide 400 μg/Formoterol Fumarate 12 μg Fixed-dose Combination BID Compared With Each Monotherapy (Aclidinium Bromide 400 μg BID and Formoterol Fumarate 12 μg BID) and Tiotropium 18 μg QD When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.

This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared to individual components and TIO (Tiotropium) 18 μg when administered to patients with stable chronic obstructive pulmonary disease (COPD).

Study Overview

• Status: Completed
• Conditions: Chronic Obstructive Pulmonary Disease
• Intervention / Treatment: Drug: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg); Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg; Drug: Aclidinium bromide 400 μg (AB 400 μg); Drug: Formoterol fumarate 12 μg (FF 12 μg); Drug: Tiotropium 18 μg (TIO 18 μg); Other: Placebo to TIO 18 μg

Detailed Description

This study was conducted to assess the bronchodilator efficacy and safety as well as effect on health related quality of life of AB/FF 400/12 μg compared to the individual components (AB 400 μg and FF 12 μg) in COPD patients. The trial duration of 24 weeks allows the assessment of the effect on symptoms improvement of the combined treatments versus individual components as well as the long term bronchodilation comparison between AB 400 μg and TIO 18 μg in minimizing the risk of COPD exacerbations in current or former smokers, aged ≥40 in symptomatic COPD patients.

• Study Type: Interventional
• Enrollment (Actual): 1595
• Phase: Phase 3

Contacts and Locations

Study Locations

• Bulgaria
  • Dimitrovgrad, Bulgaria, 6400
    • Research Site
  • Gabrovo, Bulgaria, 5300
    • Research Site
  • Roman, Bulgaria, 3130
    • Research Site
  • Ruse, Bulgaria, 7002
    • Research Site
  • Sevlievo, Bulgaria, 5400
    • Research Site
  • Sliven, Bulgaria, 8800
    • Research Site
  • Sofia, Bulgaria, 1431
    • Research Site
  • Sofia, Bulgaria, 1002
    • Research Site
  • Stara Zagora, Bulgaria, 6003
    • Research Site
  • Vidin, Bulgaria, 3700
    • Research Site
• Czechia
  • Jaromer, Czechia, 544 01
    • Research Site
  • Jindrichuv Hradec, Czechia, 377 01
    • Research Site
  • Praha 8, Czechia, 182 00
    • Research Site
  • Rokycany, Czechia, 33722
    • Research Site
  • Strakonice, Czechia, 38601
    • Research Site
• Germany
  • Berlin, Germany, 10117
    • Research Site
  • Berlin, Germany, 10717
    • Research Site
  • Berlin, Germany, 10629
    • Research Site
  • Berlin, Germany, 10787
    • Research Site
  • Berlin, Germany, 12627
    • Research Site
  • Bochum, Germany, 44787
    • Research Site
  • Dortmund, Germany, 44263
    • Research Site
  • Dresden, Germany, 01069
    • Research Site
  • Frankfurt, Germany, 60596
    • Research Site
  • Grosshansdorf, Germany, 20927
    • Research Site
  • Hamburg, Germany, 20354
    • Research Site
  • Hamburg, Germany, 20253
    • Research Site
  • Hamburg, Germany, D-22143
    • Research Site
  • Hannover, Germany, 30159
    • Research Site
  • Leipzig, Germany, 04103
    • Research Site
  • Leipzig, Germany, 04275
    • Research Site
  • Luebeck, Germany, 23552
    • Research Site
  • Marburg, Germany, 35037
    • Research Site
  • München, Germany, 80539
    • Research Site
  • Schwerin, Germany, 19055
    • Research Site
• Hungary
  • Balassagyarmat, Hungary, 2660
    • Research Site
  • Budapest, Hungary, 1036
    • Research Site
  • Debrecen, Hungary, 4031
    • Research Site
  • Gödöllő, Hungary, 2100
    • Research Site
  • Komló, Hungary, 7300
    • Research Site
  • Nyíregyháza, Hungary, 4400
    • Research Site
  • Pécs, Hungary, 7635
    • Research Site
  • Szigetszentmiklós, Hungary, 2310
    • Research Site
  • Szombathely, Hungary, 9700
    • Research Site
• Israel
  • Jerusalem, Israel, 91120
    • Research Site
  • Petach Tikva, Israel, 49100
    • Research Site
  • Rehovot, Israel, 76100
    • Research Site
• Poland
  • Bialystok, Poland, 15-003
    • Research Site
  • Częstochowa, Poland, 42-200
    • Research Site
  • Gdańsk, Poland, 80-382
    • Research Site
  • Gdynia, Poland, 81-384
    • Research Site
  • Inowrocław, Poland, 88-100
    • Research Site
  • Katowice, Poland, 40-040
    • Research Site
  • Ostrowiec Świętokrzyski, Poland, 27-400
    • Research Site
  • Pabianice, Poland, 95-200
    • Research Site
  • Szczecin, Poland, 70-111
    • Research Site
  • Warszawa, Poland, 01-192
    • Research Site
  • Wrocław, Poland, 50-088
    • Research Site
  • Zabrze, Poland, 41-800
    • Research Site
• Spain
  • Alicante, Spain, 03004
    • Research Site
  • Barcelona, Spain, 08830
    • Research Site
  • Lleida, Spain, 25198
    • Research Site
• Ukraine
  • Ivano-Frankivsk, Ukraine, 76012
    • Research Site
  • Kharkiv, Ukraine, 61039
    • Research Site
  • Kharkiv, Ukraine, 61035
    • Research Site
  • Odessa, Ukraine, 65009
    • Research Site
  • Poltava, Ukraine, 36024
    • Research Site
  • Sumy, Ukraine, 40030
    • Research Site
  • Uzhhorod, Ukraine, 88017
    • Research Site
  • Vinnytsia, Ukraine, 21018
    • Research Site
  • Zhytomyr, Ukraine, 10002
    • Research Site
• United Kingdom
  • Birmingham, United Kingdom, B15 2SQ
    • Research Site
  • Cardiff, United Kingdom, CF14 5GJ
    • Research Site
  • Chorley, United Kingdom, PR7 7NA
    • Research Site
  • Glasgow, United Kingdom, G20 OSP
    • Research Site
  • Hexham, United Kingdom, NE46 1QJ
    • Research Site
  • Liverpool, United Kingdom, L22 0LG
    • Research Site
  • Manchester, United Kingdom, M15 6SX
    • Research Site
• United States
  • Alabama
    • Gulf Shores, Alabama, United States, 36542
      • Research Site
  • Arizona
    • Phoenix, Arizona, United States, 85018
      • Research Site
    • Tucson, Arizona, United States, 85712
      • Research Site
  • California
    • Corona, California, United States, 92879
      • Research Site
    • Fresno, California, United States, 93702
      • Research Site
    • Fullerton, California, United States, 92835
      • Research Site
    • Lincoln, California, United States, 95648
      • Research Site
    • San Diego, California, United States, 92120
      • Research Site
  • Connecticut
    • Waterbury, Connecticut, United States, 06708
      • Research Site
  • Florida
    • Clearwater, Florida, United States, 33765
      • Research Site
    • Edgewater, Florida, United States, 32132
      • Research Site
    • Hollywood, Florida, United States, 33021
      • Research Site
    • Homestead, Florida, United States, 33030
      • Research Site
    • Miami, Florida, United States, 33186
      • Research Site
    • Miami, Florida, United States, 33144
      • Research Site
    • Miami Lakes, Florida, United States, 33016
      • Research Site
    • Ormond Beach, Florida, United States, 32174
      • Research Site
    • Port Orange, Florida, United States, 32129
      • Research Site
    • Saint Petersburg, Florida, United States, 33704
      • Research Site
    • Saint Petersburg, Florida, United States, 33709
      • Research Site
    • Sarasota, Florida, United States, 34233
      • Research Site
    • Tampa, Florida, United States, 33603
      • Research Site
    • Winter Park, Florida, United States, 32789
      • Research Site
  • Georgia
    • Blue Ridge, Georgia, United States, 30513
      • Research Site
    • Woodstock, Georgia, United States, 30189
      • Research Site
  • Illinois
    • Chicago, Illinois, United States, 60602
      • Research Site
  • Indiana
    • Portage, Indiana, United States, 46368
      • Research Site
  • Louisiana
    • Lafayette, Louisiana, United States, 70508
      • Research Site
  • Massachusetts
    • Fall River, Massachusetts, United States, 02720
      • Research Site
  • Michigan
    • Chelsea, Michigan, United States, 48118
      • Research Site
    • Farmington Hills, Michigan, United States, 48336
      • Research Site
    • Troy, Michigan, United States, 48085
      • Research Site
  • Minnesota
    • Edina, Minnesota, United States, 55435
      • Research Site
    • Fridley, Minnesota, United States, 55432
      • Research Site
    • Minneapolis, Minnesota, United States, 55407
      • Research Site
    • Woodbury, Minnesota, United States, 55125
      • Research Site
  • Missouri
    • Saint Charles, Missouri, United States, 63301
      • Research Site
    • Saint Louis, Missouri, United States, 63141
      • Research Site
    • Saint Louis, Missouri, United States, 63117
      • Research Site
  • Nebraska
    • Fremont, Nebraska, United States, 68025
      • Research Site
    • Omaha, Nebraska, United States, 68114
      • Research Site
    • Omaha, Nebraska, United States, 68134
      • Research Site
  • Nevada
    • Las Vegas, Nevada, United States, 89102
      • Research Site
  • New York
    • Bronx, New York, United States, 10455
      • Research Site
    • Brooklyn, New York, United States, 11230
      • Research Site
    • Buffalo, New York, United States, 14215
      • Research Site
    • New York, New York, United States, 10036
      • Research Site
    • Rochester, New York, United States, 14618
      • Research Site
  • North Carolina
    • Charlotte, North Carolina, United States, 28277
      • Research Site
    • Charlotte, North Carolina, United States, 28207
      • Research Site
    • Gastonia, North Carolina, United States, 28054
      • Research Site
    • Wilmington, North Carolina, United States, 28401
      • Research Site
  • Ohio
    • Canton, Ohio, United States, 44718
      • Research Site
    • Cincinnati, Ohio, United States, 45231
      • Research Site
    • Cincinnati, Ohio, United States, 45242
      • Research Site
    • Cincinnati, Ohio, United States, 45246
      • Research Site
    • Columbus, Ohio, United States, 43215
      • Research Site
    • Columbus, Ohio, United States, 43207
      • Research Site
    • Dublin, Ohio, United States, 43016
      • Research Site
    • Grove City, Ohio, United States, 43123
      • Research Site
  • Oklahoma
    • Edmond, Oklahoma, United States, 73034
      • Research Site
    • Midwest City, Oklahoma, United States, 73110
      • Research Site
    • Oklahoma City, Oklahoma, United States, 73104
      • Research Site
  • Oregon
    • Medford, Oregon, United States, 97504
      • Research Site
  • Pennsylvania
    • Altoona, Pennsylvania, United States, 16602
      • Research Site
    • Pittsburgh, Pennsylvania, United States, 15243
      • Research Site
    • Wyomissing, Pennsylvania, United States, 19610
      • Research Site
  • Rhode Island
    • East Providence, Rhode Island, United States, 02914
      • Research Site
  • South Carolina
    • Columbia, South Carolina, United States, 29204
      • Research Site
    • Gaffney, South Carolina, United States, 29340
      • Research Site
    • Mount Pleasant, South Carolina, United States, 29464
      • Research Site
    • Spartanburg, South Carolina, United States, 29303
      • Research Site
    • Union, South Carolina, United States, 29379
      • Research Site
  • Texas
    • Arlington, Texas, United States, 76012
      • Research Site
    • Baytown, Texas, United States, 77521
      • Research Site
    • Boerne, Texas, United States, 78006
      • Research Site
    • Dallas, Texas, United States, 75225
      • Research Site
    • Fort Worth, Texas, United States, 76104
      • Research Site
    • Houston, Texas, United States, 77074
      • Research Site
    • Lewisville, Texas, United States, 75067
      • Research Site
    • McKinney, Texas, United States, 75069
      • Research Site
    • Tomball, Texas, United States, 77375
      • Research Site
  • Utah
    • Midvale, Utah, United States, 84047
      • Research Site
  • Virginia
    • Abingdon, Virginia, United States, 24210
      • Research Site
    • Newport News, Virginia, United States, 23606
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 130 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adult male or non-pregnant, non-lactating female patients aged ≥40.
• Patients with diagnosis of moderate to very severe stable COPD: post-bronchodilator FEV1 < 80% of the predicted normal and post-bronchodilator FEV1/FVC < 70% at Screening Visit.
• Symptomatic patients with a CAT score ≥10 at Screening and Randomization visit (Visits 1 and 2).
• Current or former-smokers, with a smoking history of ≥ 10 pack-years.
• Patients able to perform acceptable and repeatable pulmonary function testing for FEV1 according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) 2005 criteria at Visit 1.
• Patients eligible and able to participate in the study and who had signed an Informed Consent Form prior to initiation of any study-related procedures.

Exclusion Criteria:

• Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or site staff), or patients employed by or relatives of the employees of the site or sponsor.
• Previous randomization in the present study D6571C00001.
• Patients with predominant asthma.
• Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation (including the mild COPD exacerbation) within 6 weeks prior to screening or during the run-in period.
• Patients hospitalized for a COPD exacerbation (an emergency room visit for longer than 24 hours is considered a hospitalization) within 3 months prior to Screening Visit.
• Clinically significant respiratory conditions other than COPD.
• Patients who in the Investigator's opinion may need to start a pulmonary rehabilitation program during the study and/or patients who started/finished it within 3 months prior to Screening.
• Use of long-term oxygen therapy (≥ 15 hours/day).
• Patients who do not maintain regular day/night, waking/sleeping cycles including night shift workers.
• Clinically significant cardiovascular conditions.
• Patients with uncontrolled Type I or Type II diabetes, uncontrolled hypo-or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled hypertension.
• Patients with history of long QT syndrome or whose QTc (calculated according to Fridericia's Formula QTc=QT/RR1/3) > 470 ms as indicated in the centralised reading report assessed at Screening.
• Patients with clinically significant abnormalities in the laboratory tests, ECG parameters (other than QTc) or in the physical examination at Screening Visit that might comprise patient safety.
• Patient with known non-controlled history of infection with human immunodeficiency virus and/or active hepatitis.
• Patient with a history of hypersensitivity reaction to inhaled medication or any component thereof, including paradoxical bronchospasm.
• Patients with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention or symptomatic non-stable prostate hypertrophy.
• History of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer.
• Patients with any other serious or uncontrolled physical or mental dysfunction.
• Patients with a history (within 2 years prior to screening) of drug and/or alcohol abuse that may prevent study compliance based on the Investigator judgment.
• Patients unlikely to be cooperative or that cannot comply with the study procedures.
• Patients treated with any investigational drug within 30 days (or 6 half-lives, whichever is longer) prior to Screening.
• Patients who intended to use any concomitant medication not permitted by this protocol or who had not undergone the required washout period for a particular prohibited medication.
• Patients unable to give consent, or patients of consenting age but under guardianship, or vulnerable patients. Patients who demonstrate < 80% compliance with the electronic diary during the run-in period.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: AB/FF 400/12 μg BID; Participants were administered AB/FF 400/12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.	Drug: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg); Inhalation powder; Other Names: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler); Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg; Inhalation powder; Other Names: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)
EXPERIMENTAL: AB 400 μg BID; Participants were administered AB 400 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.	Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg; Inhalation powder; Other Names: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler); Drug: Aclidinium bromide 400 μg (AB 400 μg); Inhalation powder; Other Names: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)
EXPERIMENTAL: FF 12 μg BID; Participants were administered FF 12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.	Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg; Inhalation powder; Other Names: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler); Drug: Formoterol fumarate 12 μg (FF 12 μg); Inhalation powder; Other Names: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)
EXPERIMENTAL: TIO 18 μg QD; Participants were administered TIO 18 μg via Handihaler® inhale once daily for 24 weeks of treatment.	Drug: Tiotropium 18 μg (TIO 18 μg); Powder in capsules for oral inhalation; Other Names: Oral Inhalation (by Handihaler® Dry Powder Inhaler, DPI); Other: Placebo to TIO 18 μg; Powder in capsules for oral inhalation; Other Names: Oral Inhalation (by Handihaler® Dry Powder Inhaler, DPI)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in 1-hour Morning Post-dose Dose Forced Expiratory Volume in 1 Second (FEV1) of AB/FF 400/12 μg Compared to AB 400 μg at Week 24	To assess the bronchodilatory effect by evaluating the mean changes from baseline in FEV1 at 1 hour post-dose of AB/FF 400/12 µg compared to AB 400 μg after administration of oral inhalation powder BID via DIP to participants with COPD. Baseline was defined as the average of the two FEV1 values measured just prior to the administration of the first dose of investigational product (IP) at randomization Visit. If one of the two was missing, then the available one would be used as baseline value.	At baseline 1-hour postdose and Week 24
Change From Baseline in Morning Predose (Trough) FEV1 of AB/FF 400/12 μg Compared to FF 12 μg at Week 24	To assess the bronchodilatory effect by evaluating the mean changes from baseline in FEV1 in morning pre-dose (trough) of AB/FF 400/12 µg compared to FF 12 μg after administration of oral inhalation powder BID via DPI to participants with COPD. Morning pre-dose (trough) FEV1 was defined as the average of the corresponding -30 minute and 0 minute before the morning study medication at Week 24. If one time-point was missing then the available one would be used as morning pre-dose.	At baseline morning predose and Week 24
Change From Baseline in Morning Predose (Trough) FEV1 at Week 24 Comparing AB 400 μg Versus TIO 18 μg to Demonstrate Non-inferiority	To assess the non-inferior bronchodilatory effect by evaluating the mean changes from baseline in FEV1 in morning pre-dose (trough)of AB 400 µg compared to TIO 18 μg after administration of oral inhalation powder BID via DPI to participants with COPD.	At baseline morning predose and Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Normalized Area Under Curve 3hours Post-dose (nAUC0-3/3h) FEV1 of AB/FF 400/12 μg Compared to AB 400 μg and and FF 12 μg at Week 24	To assess the bronchodilatory effect by evaluating the mean changes from baseline in nAUC0-3/3h FEV1 of AB/FF 400/12 µg compared to AB 400 μg and and FF 12 μg after administration of oral inhalation powder BID via DPI to participants with COPD.	At Day 1 and Day 169
Responder (Number of Participants) Analysis of St. George's Respiratory Questionnaire (SGRQ) Total Score With AB/FF 400/12 μg Versus AB 400 μg and FF 12 μg.	SGRQ was a A standardized self-completed tool used to measure impaired health and perceived well-being ("quality of life") in respiratory diseases. The questionnaire contained 50 items divided into 3 (symptoms, activity and impacts) dimensions. Each of the three dimensions of the questionnaire is scored separately in the range from 0 to 100%, zero score indicating no impairment of life quality. A summary score utilizing responses to all items is the total SGRQ score which also ranges from 0 to 100%. The SGRQ scores are calculated using weights attached to each item of the questionnaire which provides an estimate of the distress associated with the symptoms or state described in each item. Higher scores indicate poorer health. A decrease of at least 4 units in the SGRQ total score has been established as the criterion for minimal meaningful improvement. SGRQ responders will be those with a decrease in SGRQ total score of at least 4 units from baseline.	At baseline and Week 24

Collaborators and Investigators

• Sponsor: AstraZeneca
• Investigators: Principal Investigator: Sanjay Sethi, 3495 Bailey Ave , Buffalo NY14215, USA

Publications and helpful links

General Publications

• Sethi S, Kerwin E, Watz H, Ferguson GT, Mroz RM, Segarra R, Molins E, Jarreta D, Garcia Gil E. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int J Chron Obstruct Pulmon Dis. 2019 Mar 22;14:667-682. doi: 10.2147/COPD.S189138. eCollection 2019.

Helpful Links

• Protocol
• SAP

Study record dates

Study Major Dates

• Study Start (ACTUAL): July 5, 2016
• Primary Completion (ACTUAL): June 8, 2017
• Study Completion (ACTUAL): June 8, 2017

Study Registration Dates

• First Submitted: May 31, 2016
• First Submitted That Met QC Criteria: June 7, 2016
• First Posted (ESTIMATE): June 13, 2016

Study Record Updates

• Last Update Posted (ACTUAL): November 9, 2018
• Last Update Submitted That Met QC Criteria: November 7, 2018
• Last Verified: November 1, 2018

More Information

Terms related to this study

• Keywords: Safety; COPD; Efficacy; Tiotropium; Bronchodilation; Aclidinium bromide; Formoterol fumarate
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Parasympatholytics; Autonomic Agents; Peripheral Nervous System Agents; Cholinergic Antagonists; Cholinergic Agents; Adrenergic Agonists; Anticonvulsants; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Tiotropium Bromide; Bromides; Formoterol Fumarate
• Other Study ID Numbers: D6571C00001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes